Despite the effectiveness of current evidence-based treatments for PTSD and depression, many people do not benefit enough from these treatments. One exciting area of research is examining psychotherapy augmentation strategies with psychedelic drugs, a subclass of hallucinogenic drugs that trigger non-ordinary states of consciousness. They “alter perception and mood and affect numerous cognitive processes” (1). Two specific psychedelic compounds, MDMA (often referred to as a non-classic psychedelic) and psilocybin, have received most of the research attention to date. While these are both still Schedule I substances—drugs with high abuse potential and no currently accepted medical use—ongoing research efforts have found support for using these compounds in conjunction with therapy to treat various mental health conditions, including PTSD. The Veterans Health Administration’s (VHA) Office of Research Development (ORD) is funding research on psychedelic compounds in Veterans.